未知股票 BIOL 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 3659.71万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 2.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Cepi And Samsung Biologics Collaborate To Strengthen Outbreak-Ready Vaccine Production And Global Access
BRIEF-Cepi And Samsung Biologics Collaborate To Strengthen Outbreak-Ready Vaccine Production And Global Access Feb 3 (Reuters) - Samsung Biologics Co Ltd 207940.KS : CEPI AND SAMSUNG BIOLOGICS COLLABORATE TO STRENGTHEN OUTBREAK-READY VACCINE PRODUCTION AND GLOBAL ACCESS Source text: ID:nPn9NK986a Fu
02-03 21:33
BRIEF-Eisai & Biogen Say U.S. FDA Accepts Leqembi Supplemental Biologics License Application As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Under Priority Review
BRIEF-Eisai & Biogen Say U.S. FDA Accepts Leqembi Supplemental Biologics License Application As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Under Priority Review Jan 25 (Reuters) - Eisai Co Ltd 4523.T : FDA ACCEPTS LEQEMBI® IQLIKTM (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE AP
01-26 07:36
BRIEF-Scholar Rock Holding To Submit MAA To EMA In 1Q 2025
Jan 29 (Reuters) - Scholar Rock Holding Corp SRRK.O: SCHOLAR ROCK SUBMITS BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FDA FOR APITEGROMAB AS A TREATMENT FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY (...
2025-01-29 21:07
BRIEF-Cosmos Health Signs Expanded Exclusive Distribution Agreement With Virax Biolabs For Avian Influenza Virus PCR Kits
Jan 23 (Reuters) - Cosmos Health Inc COSM.O: COSMOS HEALTH: EXPANDED EXCLUSIVE DISTRIBUTION AGREEMENT WITH VIRAX BIOLABS FOR AVIAN INFLUENZA VIRUS PCR KITS IN SAUDI ARABIA, UAE, QATAR, KUWAIT Further ...
2025-01-24 04:40
BRIEF-Ocugen Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Jan 16 (Reuters) - Ocugen Inc OCGN.O: OCUGEN, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF OCU200—A NOVEL INTEGRIN-TARGETING BIOLOGIC FOR DIABETIC MACULAR EDEMA OCUGEN INC - TO PURS...
2025-01-16 20:36
BRIEF-UCB, XtalPi Unit Partner Up On Biologics AI Platform
Jan 9 (Reuters) - Ucb SA UCB.BR: PARTNERS WITH AILUX BIOLOGICS, A DIVISION OF XTALPI, ON BIOLOGICS AI PLATFORM Further company coverage: UCB.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; ...
2025-01-09 14:03
BRIEF-Mirror Biologics and Merck KGaA Enter Clinical Trial Collaboration And Supply Agreement
Jan 8 (Reuters) - Merck KGaA MRCG.DE: MIRROR BIOLOGICS: ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK KGAA Source text: ID:nGNX7VmpYq Further company coverage: MRCG.DE ((...
2025-01-08 20:07
BRIEF-Capricor Therapeutics Completes Submission Of Biologics License Application To The U.S. FDA For Deramiocel
Jan 2 (Reuters) - Capricor Therapeutics Inc CAPR.O: CAPRICOR THERAPEUTICS COMPLETES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FDA FOR DERAMIOCEL FOR THE TREATMENT OF DUCHENNE MUSCULAR DY...
2025-01-02 22:21
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tues...
2024-06-19 04:31
BIOLASE announces delisting from Nasdaq
BIOLASE (NASDAQ:BIOL) on Tuesday said it has received a notice from Nasdaq that it has determined to delist the shares of the company's common stock from Nasdaq Stock Market. The delisting is a result...
2024-06-19 04:10
